Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Sensors used to monitor dangerous hits on football field

  • 'Abandoned' stroke survivors need better longer-term care, expert says

  • Black Republicans put most faith in US government

  • Bedside caregivers: Research shows opening visitation access improves patient satisfaction

  • Expectant mothers with epilepsy face tough choices over their medication

  • Possible cause of common dementia found, opening avenues for treatment

  • Lou Gehrig's disease study: Renewing brain's aging support cells may help neurons survive

  • Minutes in Criminal Procedures: Writing Style Influences Judges

  • Greater inequality within UK, USA than some developing countries, trade 'footprint' shows

  • Even mild depressive symptoms result in poorer lumbar spinal stenosis surgery outcome

  •